KR101719339B1 - 혈소판 수준을 증가시키는 펩타이드 요법 - Google Patents

혈소판 수준을 증가시키는 펩타이드 요법 Download PDF

Info

Publication number
KR101719339B1
KR101719339B1 KR1020127000921A KR20127000921A KR101719339B1 KR 101719339 B1 KR101719339 B1 KR 101719339B1 KR 1020127000921 A KR1020127000921 A KR 1020127000921A KR 20127000921 A KR20127000921 A KR 20127000921A KR 101719339 B1 KR101719339 B1 KR 101719339B1
Authority
KR
South Korea
Prior art keywords
arg
mod
res
xaa
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127000921A
Other languages
English (en)
Korean (ko)
Other versions
KR20120037463A (ko
Inventor
미셀 아브라함
암논 펠레드
오를리 아이젠버그
Original Assignee
바이오카인 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오카인 테라퓨틱스 리미티드 filed Critical 바이오카인 테라퓨틱스 리미티드
Publication of KR20120037463A publication Critical patent/KR20120037463A/ko
Application granted granted Critical
Publication of KR101719339B1 publication Critical patent/KR101719339B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020127000921A 2009-06-14 2010-06-13 혈소판 수준을 증가시키는 펩타이드 요법 Active KR101719339B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18685709P 2009-06-14 2009-06-14
US61/186,857 2009-06-14
PCT/IL2010/000466 WO2010146578A2 (en) 2009-06-14 2010-06-13 Peptide therapy for increasing platelet levels

Publications (2)

Publication Number Publication Date
KR20120037463A KR20120037463A (ko) 2012-04-19
KR101719339B1 true KR101719339B1 (ko) 2017-03-23

Family

ID=43356827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127000921A Active KR101719339B1 (ko) 2009-06-14 2010-06-13 혈소판 수준을 증가시키는 펩타이드 요법

Country Status (11)

Country Link
US (1) US9427456B2 (enExample)
EP (1) EP2442822B1 (enExample)
JP (1) JP5715622B2 (enExample)
KR (1) KR101719339B1 (enExample)
CN (1) CN102481332A (enExample)
BR (1) BRPI1009663A2 (enExample)
CA (1) CA2765345C (enExample)
ES (1) ES2462517T3 (enExample)
IL (1) IL216912A (enExample)
MX (1) MX2011013459A (enExample)
WO (1) WO2010146578A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
EP2663320A1 (en) 2011-01-10 2013-11-20 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
WO2014089478A1 (en) * 2012-12-07 2014-06-12 University Of Tennessee Research Foundation Methods of numerical analysis for platelet disorders and computer-readable media and systems for performing the same
CA3037762C (en) * 2014-05-15 2022-03-22 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
JP6547274B2 (ja) 2014-10-20 2019-07-24 株式会社デンソー 粒子状物質検出センサ
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
MX2018010125A (es) 2016-02-23 2019-03-28 Biolinerx Ltd Procedimientos de tratamiento de leucemia mieloide aguda.
CN113905754B (zh) * 2019-01-25 2025-03-11 詹森药业有限公司 减轻起疱剂和腐蚀性气体毒性作用的方法
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂
CN116801896A (zh) 2020-12-30 2023-09-22 百欧林纳克斯有限公司 Bl-8040的组合物
WO2022144886A1 (en) 2020-12-30 2022-07-07 Biolinerx Ltd. Process for manufacturing peptide
CN118027155B (zh) * 2024-04-15 2024-07-16 中国人民解放军军事科学院军事医学研究院 一种tpor结合肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
WO2008075369A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0396158A1 (en) 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (de) 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
ATE65403T1 (de) 1986-01-22 1991-08-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
EP0231819B1 (en) 1986-01-22 1992-04-01 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for the treatment of myelogenous leukemia
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68918331T2 (de) 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5202117A (en) 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5776899A (en) 1993-10-14 1998-07-07 Seikagaku Corporation Polypeptide and anti-HIV agent prepared therefrom
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5492126A (en) 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
EP0983082A1 (en) * 1997-05-21 2000-03-08 Genentech, Inc. Novel administration of thrombopoietin
EP0998217B1 (en) 1997-05-23 2009-01-07 ProRhythm, Inc. Disposable high intensity focused ultrasound applicator
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
WO2000006086A2 (en) 1998-07-31 2000-02-10 The Trustees Of Columbia University In The City Of New York Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
PL202399B1 (pl) 1998-10-05 2009-06-30 Pharmexa As Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an
WO2000024468A1 (de) 1998-10-27 2000-05-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6630480B1 (en) 1999-03-29 2003-10-07 Biochem Pharma Inc. Methods of treating leukemia
MXPA02005199A (es) 1999-11-24 2002-11-07 Schering Corp Metodos para inhibir metastasis.
WO2001064716A1 (fr) 2000-03-03 2001-09-07 Nobutaka Fujii Composes antiviraux
DE60103052T2 (de) * 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
DE60136373D1 (de) 2000-09-05 2008-12-11 Biokine Therapeutics Ltd Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (ja) 2001-02-16 2003-02-10 サンケン電気株式会社 スイッチング電源装置
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
JP4666256B2 (ja) 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
CA2520406A1 (en) * 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
CN1838965B (zh) 2004-03-19 2011-07-06 森永乳业株式会社 用于癌症治疗的药品
CA2577046A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
CN101365336B (zh) 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
CN101573441A (zh) 2005-12-08 2009-11-04 路易斯维尔大学研究基金会有限公司 非常小的胚胎样（vsel）干细胞及分离和利用其的方法
EP2489728A1 (en) 2006-06-15 2012-08-22 Neostem, Inc Processing procedure for peripheral blood stem cells
AR063470A1 (es) 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
EP2058395A4 (en) 2006-08-04 2009-12-09 Univ Kurume PEPTIDE DERIVED FROM KIF WITH THE ABILITY TO BIND TO HLA-A24 MOLECULAR
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
CN102482324B (zh) 2009-06-15 2014-07-02 拜欧肯疗法有限公司 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽
US20120082687A1 (en) 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
EP2663320A1 (en) 2011-01-10 2013-11-20 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CA2906314A1 (en) 2013-03-24 2014-10-02 Biolinerx Ltd. Methods of treating myeloid leukemia
JP2016527303A (ja) 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
ES2811804T3 (es) 2013-10-31 2021-03-15 Biokine Therapeutics Ltd Un inhibidor peptídico de CXCR4 para su uso en el tratamiento de la leucemia mieloide aguda con una mutación de FLT3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
WO2008075369A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Alimentary Pharmacology & Therapeutics. Vol. 26, Suppl 1, pp. 29-39 (2007)*

Also Published As

Publication number Publication date
US20120094907A1 (en) 2012-04-19
CA2765345C (en) 2016-06-21
WO2010146578A3 (en) 2011-02-10
CN102481332A (zh) 2012-05-30
JP5715622B2 (ja) 2015-05-07
JP2012530130A (ja) 2012-11-29
EP2442822B1 (en) 2014-03-05
WO2010146578A2 (en) 2010-12-23
IL216912A (en) 2015-09-24
KR20120037463A (ko) 2012-04-19
EP2442822A2 (en) 2012-04-25
US9427456B2 (en) 2016-08-30
ES2462517T3 (es) 2014-05-23
IL216912A0 (en) 2012-02-29
MX2011013459A (es) 2012-05-08
BRPI1009663A2 (pt) 2016-10-11
CA2765345A1 (en) 2010-12-23
EP2442822A4 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
KR101719339B1 (ko) 혈소판 수준을 증가시키는 펩타이드 요법
EP3011961B1 (en) 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
JP5315372B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
US9155780B2 (en) Short beta-defensin-derived peptides
US20130303460A1 (en) Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
ES2643321T3 (es) Una combinación de un antagonista de CXCR4 y citarabina para su uso en el tratamiento de la leucemia mieloide
EP2007416B1 (en) Paratyroid hormone (pth) for use in the treatment of ischemia
JP4781621B2 (ja) Ｃｘｃｒ４拮抗薬およびその用途
HK1220899B (en) 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
JP2008519032A (ja) Ｆｇｆ−２０の調合物、生成方法および使用
CA2738757A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
TW200808341A (en) Use of TPO peptide compounds and pharmaceutical compositions in the treatment of anemia
TW201704258A (zh) 調控免疫反應之方法及多肽
KR20080094946A (ko) 빈혈 치료에서의 ｔｐｏ 펩티드 화합물 및 약학 조성물의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150611

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161010

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170227

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170317

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170317

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200306

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210305

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220304

Start annual number: 6

End annual number: 6